Navigation Links
PharmaVentures Advises 3Legs Resources on its Acquisition of the Immuno-Oncology Company SalvaRx Who Announced its Admission for Trading on AIM Today
Date:3/22/2016

OXFORD, England, March 22, 2016 /PRNewswire/ --

PharmaVentures is pleased to announce that it acted as an independent technical and commercial expert adviser to 3Legs on its Reverse Takeover of SalvaRx. 3Legs Resources is an investment company that focuses on life sciences and related technologies. 

SalvaRx is an immuno-oncology company developing novel therapeutics that stimulate the immune system to fight cancer. SalvaRx also owns over 60% of iOx Therapeutics, which is developing anti-cancer treatments based on invariant natural killer T-cells and is poised to undertake the first Phase I/II human trials.

Adrian Dawkes, Vice President, PharmaVentures said; "In the pivotal area of immuno-oncology we were pleased to be able to provide an expert assessment of the iOx technology to support 3Legs in its acquisition."

Fintan Walton, Chief Executive of PharmaVentures said: "This is the twelfth independent expert report we have provided for companies raising finance, and the third during the recent upturn in IPO activities in the UK. Expert commercial and technical insight is a key component in company acquisitions especially where public markets are involved. PharmaVentures is able to provide valuable advisory services for our clients via our deep knowledge of the pharmaceutical and biotechnology sectors."

For over 23 years, PharmaVentures has acted as advisor to over 700 pharmaceutical and biotechnology clients in transactions; covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.

About PharmaVentures, Ltd

PharmaVentures is a premier transaction advisory firm; a leader in partnering, M&A deals and strategic alliances. 

An unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes them uniquely placed to support your business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

Find out more http://www.pharmaventures.com

Their services include: 

  • M&A (divestments, mergers, acquisitions and strategic transactions)
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
  • Licensing (in and out licensing)
  • Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)

Now in its 24th year, PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in N. America, Latin America, and Asia-Pacific.


'/>"/>
SOURCE PharmaVentures
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. PharmaVentures Advises Transgene on the Sale of Their Biopharmaceutical Manufacturing Plant
2. R&D Tax Services Firm Tri-Merit Advises Businesses on IRS Warning
3. Transwestern
4. RBJ Advises Shire in 202,000 SF Lease, Creating Bostons Largest Suburban Biotech Campus
5. Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Bostons Largest Suburban Biotech Campus
6. Covington Advises Salix in $2.6 Billion Acquisition of Santarus
7. Cadwalader Advises Elan Corporation in Billion Dollar Royalty Deal
8. Couple Catches Bed Bug in a Hotel, My Cleaning Products Advises Hotel Management to Counter the Pests With Non-Pesticide Bed Bug Spray Bed Bug Bully
9. Woman Menaces Worker Trying to Get Rid of Bed Bugs, My Cleaning Products Advises She Gets a Non-Pesticide Bed Bug Spray if She Wants No Help
10. Bed Bugs Rise in Oneida County, My Cleaning Products Cautions Residents and Advises Them to Have a Bed Bug Bully Prepared
11. Bed Bugs Sneak In to Elementary Schools, My Cleaning Products Advises to Officials and Other Bed Bug Victims Use of Pesticide-Exempt Bed Bug Bully
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
Breaking Biology Technology:
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
Breaking Biology News(10 mins):